Central Nervous System News and Research

RSS

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

CeloNova BioSciences today announced that the company is submitting to its European Notified Body a request for approval of its new, lime green, 2800 micron size Embozene(TM) Microsphere.

31 Oct 2009

NeuroVigil and Roche collaborate to speed up drug development for CNS disorders

Today, leading California Neurotechnology company NeuroVigil and Swiss Pharma giant Roche announced an agreement regarding a major innovation in collecting and analyzing data from clinical trials.

30 Oct 2009

Positive top-line results from Phase IIb clinical trial of cariprazine announced

Forest Laboratories, Inc. and Gedeon Richter Plc today announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.

29 Oct 2009

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. (“Amarantus”) and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer.

29 Oct 2009

Regeneration of central nervous system axons can be achieved: Study

Scientists at the University of California, San Diego School of Medicine report that regeneration of central nervous system axons can be achieved in rats even when treatment delayed is more than a year after the original spinal cord injury.

29 Oct 2009

CNS Response to present results from depression efficacy study at U.S. Psychiatric and Mental Health Congress

CNS Response, Inc. announced that the company will present top-line results from its multi-site clinical trial next week at the U.S. Psychiatric and Mental Health Congress. "Referenced-EEG (rEEG®) Efficacy Compared to Star*D for Patients with Depression Treatment Failure: First Look at Final Results," will be presented by Charles DeBattista, M.D. on Monday, November 2nd, at 3:45 to 6:45 p.m. The conference is being held at the Mandalay Bay South Convention Center in Las Vegas, NV.

29 Oct 2009

Brain cell transplants help replace degenerated neurons, finds Swiss research team

A Swiss research team has found that using an animal's own brain cells (autologous transplant) to replace degenerated neurons in select brain areas of donor primates with simulated but asymptomatic Parkinson's disease and previously in a motor cortex lesion model, provides a degree of brain protection and may be useful in repairing brain lesions and restoring function.

29 Oct 2009

Medtronic announces the international launch of PoleStar N30 Surgical MRI system

This week at the annual Congress of Neurological Surgeons (CNS), Medtronic (NYSE: MDT) announced the Conformite Europeen (CE) mark and international launch of the PoleStar® N30 Surgical MRI system, the latest in neuro oncology surgical solutions.

28 Oct 2009

Ziehm NaviPort interface and BrainLAB Fluoro 3D surgical navigation software improves surgical procedures

Ziehm Imaging and BrainLAB have extended their cooperation to assist surgeons in the intra-operative guidance of pedicle screw and hardware placement during surgical trauma and spinal instrumentation procedures.

27 Oct 2009

New significant tool to improve the quality of care for patients with brain tumors released

While the nation is debating how best to reform healthcare, the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) announce a new significant tool to improve the quality of care for patients who suffer from brain tumors.

27 Oct 2009

Innovative approach to build a new drug to treat a number of CNS diseases

Working like an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University's Sackler School of Medicine is "building" a new drug, L803-MTS, to treat a number of central nervous system (CNS) diseases like Alzheimer's. In pre-clinical studies, it also shows promise against Parkinson's, Huntington's and diabetes.

27 Oct 2009

In the House, Democrats opposed to abortion threaten reform bill

Some House Democrats opposed to abortion are threatening to thwart health care reform legislation if it does not clearly steer away from funding abortions. Congress Daily reports: "With Republicans likely to try to use the emotional issue to draw support and money for 2010 contests, Democrats tried to make the bill 'abortion neutral' -- maintaining existing federal policy without further restricting abortion rights.

26 Oct 2009

Results from Phase I dose-escalation study of AT-101 announced

Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).

26 Oct 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

26 Oct 2009

Enzyme Mst3b is essential for regenerating damaged axons in live animal model, say researchers

Researchers at Children's Hospital Boston report that an enzyme known as Mst3b, previously identified in their lab, is essential for regenerating damaged axons (nerve fibers) in a live animal model, in both the peripheral and central nervous systems.

26 Oct 2009

Democratic infighting on abortion and health reform will peak this week

Examiner: "House Speaker Nancy Pelosi (D-CA) intends to bring the legislation to the floor early this week, but Pro-life Representative Bart Stupak (D-MI) and a posse of conservative Democrats might just throw a wrench in Pelosi's plans.

26 Oct 2009

Orthovita to present comparative study data of its Cortoss product to polymethylmethacrylate

Orthovita, Inc., an orthobiologics and biosurgery company, is pleased to announce that Dr. Pierce D. Nunley, Director of the Spine Institute of Louisiana, will present his abstract, “A Comparison of Clinical Outcomes and Adjacent Level Fractures in Patients Receiving Vertebroplasty for Osteoporotic Compression Fractures Using CortossTM or PMMA: A Prospective, Randomized Trial,” at the 2009 Annual Meeting of the Congress of Neurological Surgeons (CNS).

24 Oct 2009

Elekta to demonstrate stereotactic solutions at the 2009 CNS Annual Meeting

At the 2009 Congress of Neurological Surgeons (CNS) Annual Meeting, October 24-28 in New Orleans, Louisiana, Elekta will demonstrate how its line of stereotactic solutions expand treatment capabilities and bring new hope for patients presenting serious conditions.

From Elekta 24 Oct 2009

University neurologists launch multiple sclerosis research study

Neurologists at the University at Buffalo are beginning a research study that could overturn the prevailing wisdom on the cause of multiple sclerosis (MS).

24 Oct 2009

Updated data on XL184 study in patients with glioblastoma multiforme presented

Exelixis, Inc. and Bristol-Myers Squibb Company today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

24 Oct 2009

Central Nervous System News and Research

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

NeuroVigil and Roche collaborate to speed up drug development for CNS disorders

Positive top-line results from Phase IIb clinical trial of cariprazine announced

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

Regeneration of central nervous system axons can be achieved: Study

CNS Response to present results from depression efficacy study at U.S. Psychiatric and Mental Health Congress

Brain cell transplants help replace degenerated neurons, finds Swiss research team

Medtronic announces the international launch of PoleStar N30 Surgical MRI system

Ziehm NaviPort interface and BrainLAB Fluoro 3D surgical navigation software improves surgical procedures

New significant tool to improve the quality of care for patients with brain tumors released

Innovative approach to build a new drug to treat a number of CNS diseases

In the House, Democrats opposed to abortion threaten reform bill

Results from Phase I dose-escalation study of AT-101 announced

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Enzyme Mst3b is essential for regenerating damaged axons in live animal model, say researchers

Democratic infighting on abortion and health reform will peak this week

Orthovita to present comparative study data of its Cortoss product to polymethylmethacrylate

Elekta to demonstrate stereotactic solutions at the 2009 CNS Annual Meeting

University neurologists launch multiple sclerosis research study

Updated data on XL184 study in patients with glioblastoma multiforme presented

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News